Abstract
Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.
Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.
Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p
Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.
Original language | English |
---|---|
Pages (from-to) | 105-113 |
Number of pages | 9 |
Journal | Journal of Nephrology |
Volume | 28 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Ferric citrate
- Hemodialysis
- Iron metabolism
- Phosphate
ASJC Scopus subject areas
- Nephrology